Literature DB >> 32714535

Small-cell lung carcinoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report.

Ryota Otoshi1, Akimasa Sekine1, Koji Okudela2, Masato Asaoka1, Yozo Sato1, Satoshi Ikeda1, Tomohisa Baba1, Shigeru Komatsu1, Eri Hagiwara1, Takashi Ogura1.   

Abstract

The present report describes a case of a 68-year-old male patient with epidermal growth factor receptor (EGFR)-mutant non-small cell lung carcinoma (NSCLC). After cytotoxic chemotherapy of three regimens following 22 months of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, the patient underwent S-1 treatment. Despite a decrease in carcinoembryonic antigen 1 month after initiating S-1 treatment, the patient developed cardiac tamponade. The evaluation of pericardial effusion confirmed small-cell lung carcinoma (SCLC) transformation. Subsequently, a combination therapy of carboplatin and etoposide was administered, which led to a marked improvement in imaging. In patients with NSCLC who develop pericardial effusion after long-term EGFR-TKI therapy, including osimertinib treatment, it is important to investigate whether SCLC transformation occurs or not as a treatable entity. Copyright: © Otoshi et al.

Entities:  

Keywords:  adenocarcinoma; epidermal growth factor receptor; osimertinib; pericardial effusion; small-cell lung carcinoma transformation

Year:  2020        PMID: 32714535      PMCID: PMC7366234          DOI: 10.3892/mco.2020.2059

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  14 in total

1.  [Clinical studies of 16 cases of carcinomatous pericarditis].

Authors:  M Hayano; Y Hokamura; Y Kimura; T Kimura; K Tokube
Journal:  Kokyu To Junkan       Date:  1991-07

Review 2.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors:  Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

3.  Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.

Authors:  Yuki Iijima; Yosuke Hirotsu; Hitoshi Mochizuki; Kenji Amemiya; Toshio Oyama; Yoshinori Uchida; Yoichi Kobayashi; Toshiharu Tsutsui; Yumiko Kakizaki; Yoshihiro Miyashita; Masao Omata
Journal:  Clin Lung Cancer       Date:  2018-07-26       Impact factor: 4.785

4.  EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Authors:  Nicolas Marcoux; Scott N Gettinger; Grainne O'Kane; Kathryn C Arbour; Joel W Neal; Hatim Husain; Tracey L Evans; Julie R Brahmer; Alona Muzikansky; Philip D Bonomi; Salvatore Del Prete; Anna Wurtz; Anna F Farago; Dora Dias-Santagata; Mari Mino-Kenudson; Karen L Reckamp; Helena A Yu; Heather A Wakelee; Frances A Shepherd; Zofia Piotrowska; Lecia V Sequist
Journal:  J Clin Oncol       Date:  2018-12-14       Impact factor: 44.544

5.  Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer.

Authors:  P C Wang; K Y Yang; J Y Chao; J M Liu; R P Perng; S H Yen
Journal:  Chest       Date:  2000-09       Impact factor: 9.410

6.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.

Authors:  Tae Min Kim; Ahnah Song; Dong-Wan Kim; Soyeon Kim; Yong-Oon Ahn; Bhumsuk Keam; Yoon Kyung Jeon; Se-Hoon Lee; Doo Hyun Chung; Dae Seog Heo
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

9.  Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.

Authors:  Yuri Taniguchi; Hajime Horiuchi; Teppei Morikawa; Kazuhiro Usui
Journal:  Case Rep Oncol       Date:  2018-05-29

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.